Global Hemophilia Market Size, Share, and COVID-19 Impact Analysis, By Treatment (On-demand, Prophylaxis), By Therapy (Immune Tolerance Induction (ITI) Therapy, Replacement Therapy, Gene Therapy), By End Use (Hospital Pharmacies, Retail Pharmacy, Others), by Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2021 – 2030.Industry: Healthcare
Global Hemophilia Market Insights Forecasts to 2030
- The Hemophilia market was valued at USD 12.1 billion in 2021.
- The market is growing at a CAGR of 7.55% from 2022 to 2030
- The global Hemophilia market is expected to reach USD 17.8 billion by 2030
- Asia Pacific is expected to grow the fastest during the forecast period
Get more details on this report -
The Global Hemophilia market is expected to reach USD 17.8 billion by 2030, at a CAGR of 7.55% during the forecast period 2022 to 2030.
A person with haemophilia A has low or no levels of the clotting factor VIII protein. FVIII replacement therapy has long been the standard of care. FVIII replacement was first performed using donated whole blood, then plasma, and most recently, recombinant human FVIII (rFVIII) replacement therapies, which completely changed how Hemophilia A was treated. Hemophilia can also be developed later in life if the body starts to produce antibodies that attack and destroy clotting factors, despite the fact that it is typically diagnosed at birth. This acquired haemophilia, however, is quite uncommon.
Global Hemophilia Market Report Coverage
|Market Size in 2021:||USD 12.1 Billion|
|Forecast Period:||2021 - 2030|
|Forecast Period 2021 - 2030 CAGR:||7.55%|
|2030 Value Projection:||USD 17.8 Billion|
|Historical Data for:||2017 - 2020|
|No. of Pages:||210|
|Tables, Charts & Figures:||122|
|Segments covered:||By Treatment, By Therapy, By End Use, By Region|
|Companies Covered:||Bayer AG, CSL Ltd. (CSL Behring), F. Hoffmann-La Roche AG, Grifols, S.A, Medexus Pharmaceuticals Inc., Novo Nordisk A/S, octapharma ag, Pfizer Inc., Swedish Orphan Biovitrum AB, Takeda Pharmaceuticals Company ltd|
|Pitfalls & Challenges:||COVID-19 Empact, Challenge, Future, Growth, & Analysis|
Get more details on this report -
This research report categorizes the market for Hemophilia market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Hemophilia market. Recent market developments and competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segments of the Hemophilia market.
R&D activities are expanding as a result of the availability of few therapeutic therapy options and the mounting burden on regulatory authorities to address it. The term "ecosystem" refers to a group of people who work in the construction industry. Increased haemophilia prevalence, improvements in haemophilia treatment technology, and supportive governmental measures for haemophilia management are all contributing factors to the growth of the haemophilia treatment market share.
The market's expansion is anticipated to be constrained by the high cost of haemophilia treatment, a lack of haemophilia medications, and major adverse effects linked to plasma-derived products.
The market for haemophilia treatments is growing due to the variety of therapy and medications available. Some typical treatments and therapies for haemophilia include inhibitor therapy, over-the-counter remedies, free factor replacement therapy, antifibrinolytic pharmaceuticals, gene therapy, and physical therapy. The market for haemophilia treatments has grown significantly as a result of these causes. The market for haemophilia treatments has grown recently due to expanding government initiatives and aggressive political campaigns. In recent years, haemophilia treatment and facilities have improved, particularly in accordance with medical recommendations for COVID immunisation.
- In 2021, the On Demand holds the largest market share over the forecast period.
On the basis of treatment, the hemophilia market is segmented into prophylaxis and on-demand treatment. Among these, the on demand holds the largest market share over the forecast period. On the other hand, propphylaxis segment is witnessing the fastest market growth over the forecast period. Prophylaxis, which involves administering clotting factor concentrates on a regular basis to individuals with severe haemophilia, is a well established treatment that is causing its growing rate. The severity of the patients determines how long this treatment will last. Prophylaxis treatment is also projected to improve quality of life while reducing productivity loss.
- In 2021, the Replacement Therapy is dominating the market with the largest market share over the forecast period.
Based on the therapy, the hemophilia market is segmented into immune tolerance induction (ITI) therapy, replacement therapy, and gene therapy. Among these, the replacement therapy is dominating the market with the largest market share over the forecast period. Replacement therapy, which aids in replacing the patients' lost clotting factor, is regarded as the gold standard in treatment. One of the newer fields is gene therapy, which focuses on finding damaged DNA bases and replacing them with functional ones. Clinical trials are currently being conducted on AMT-060, a possible medication created by UniQure for the treatment of type B. By implanting a functional copy of the factor IX gene into the liver cells of type B patients, the therapy helps patients resume producing factor IX.
- In 2021, the Hospital segment is dominating the market with the largest market share over the forecast period.
On the basis of end user, the hemophilia market is segmented into hospital pharmacies, retail pharmacy, and others. Among these, the hospital segment is dominating the market with the largest market share over the forecast period. The hospital segment is attributable to the prospects for board certification for knowledgeable haematologists, the significance of providing quality treatment plans, and the efficiency increases they produce. These healthcare facilities provide treatments at reasonable costs to benefit both patients and insurance companies. Hospital preferences for the treatment of bleeding disorders have increased because to the simple accessibility of new medicines. Additionally, it is anticipated that thorough hospital care plans and ongoing monitoring will improve patient choice for these drug healthcare facilities. As a result, this genetic bleeding condition is causing an increase in hospital admissions. It is anticipated that the demand for enhanced treatment will promote product uptake in these facilities.
Regional Segment Analysis of the Hemophilia Market
- North America (U.S., Canada, Mexico)
- Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
- Asia-Pacific (China, Japan, India, Rest of APAC)
- South America (Brazil and the Rest of South America)
- The Middle East and Africa (UAE, South Africa, Rest of MEA)
Get more details on this report -
North America is dominating the market with the largest market share over the forecast period.
Among all other regions, the North America is dominating the market with the largest market share over the forecast period. Preliminary drivers of regional growth are anticipated to include increasing prevalence and a growing propensity for prophylactic medication. People in the US are diagnosed with this illness at relatively young ages. On the other hand, over the predicted period, Asia-Pacific is expected to experience the strongest increase. The important impact-producing factors are increased per capita usage of medicines for factor VIII and IX insufficiency and early detection of the disorders in nations like Japan, India, Indonesia, and Malaysia.
- In 2018, To increase its market share in the field of rare diseases, Sanofi paid USD 11.6 billion for the haemophilia expert Bioverativ.
- In July 2021, for adults with severe haemophilia A, BioMarin Pharmaceutical Inc.'s investigational gene treatment valoctocogene roxaparvovec has received marketing approval from the European Medicines Agency (EMA).
The report offers the appropriate analysis of the key organizations/companies involved within the global Hemophilia market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
List of Key Companies
- Bayer AG, CSL Ltd. (CSL Behring)
- F. Hoffmann-La Roche AG
- Medexus Pharmaceuticals Inc.
- Novo Nordisk A/S
- octapharma ag
- Pfizer Inc.
- Swedish Orphan Biovitrum AB
- Takeda Pharmaceuticals Company ltd
Key Target Audience
- Market Players
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
This study forecasts revenue at global, regional, and country levels from 2021 to 2030. Spherical Insights has segmented the global Hemophilia market based on the below-mentioned segments:
Hemophilia Market, By Treatment
Hemophilia Market, By Therapy
- Replacement Therapy
- ITI Therapy
- Gene Therapy
Hemophilia Market, By End User
- Hospital Pharmacy
- Retail Pharmacy
Hemophilia Market, Regional Analysis
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- South America
- Rest of South America
- Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
Need help to buy this report?